|Bid||0.00 x 800|
|Ask||0.00 x 1100|
|Day's Range||404.40 - 409.65|
|52 Week Range||281.89 - 442.00|
|Beta (3Y Monthly)||0.93|
|PE Ratio (TTM)||19.12|
|Earnings Date||May 1, 2019 - May 6, 2019|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||430.24|
Regeneron Pharmaceuticals Inc NASDAQ/NGS:REGNView full report here! Summary * ETFs holding this stock are seeing positive inflows * Bearish sentiment is low Bearish sentimentShort interest | PositiveShort interest is extremely low for REGN with fewer than 1% of shares on loan. This could indicate that investors who seek to profit from falling equity prices are not currently targeting REGN. Money flowETF/Index ownership | PositiveETF activity is positive. Over the last month, ETFs holding REGN are favorable, with net inflows of $11.35 billion. Additionally, the rate of inflows is increasing. Economic sentimentPMI by IHS Markit | NeutralAccording to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is weak relative to the trend shown over the past year, however. Credit worthinessCredit default swapCDS data is not available for this security.Please send all inquiries related to the report to firstname.lastname@example.org.Charts and report PDFs will only be available for 30 days after publishing.This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.
Regeneron (REGN) and partner Sanofi receives approval in Europe for the label expansion of Praluent to reduce cardiovascular (CV) risk in adults with established atherosclerotic CV disease.
Inovio's (INO) most advanced candidate, VGX-3100 vaccine, is advancing well. Heavy reliance on partners for funds to develop its pipeline candidates is a persistent concern.
The stock surged as much as 118 percent on Monday, the most ever, after data showed that its experimental therapy for atopic dermatitis, or eczema, demonstrated results that were better than Regeneron Pharmaceuticals and Sanofi’s star drug Dupixent. Regeneron shares fell 1 percent. Dupixent is forecast to generate $4.65 billion in sales by 2022, overtaking Eylea as the company’s largest drug, according to estimates compiled by Bloomberg.
Praluent ® (alirocumab) now approved in European Union to reduce the risk of cardiovascular events in patients with established cardiovascular disease Approval is based on ODYSSEY OUTCOMES trial of 18,924 ...
If you use charts well, you can find the right time to buy the best growth stocks early in their run. After a breakout, look for places to add shares.
Though most of the stocks in the S&P 500 ETF have delivered astounding returns during the decade, a few were the real stars, skyrocketing more than 2000%.
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today announced that four new sub-analyses from the Praluent® (alirocumab) ODYSSEY OUTCOMES cardiovascular (CV) outcomes trial will be presented at the American College of Cardiology's 68th Annual Scientific Session (ACC.19), held March 16-18, in New Orleans, LA. A Featured Clinical Research presentation that evaluates the impact of lowering lipoprotein(a) [Lp(a)] with Praluent on total CV events, independent of low-density lipoprotein cholesterol (LDL-C) reduction. An oral presentation that shows Praluent treatment was associated with larger reductions in the risk of major adverse CV events (MACE) and death in patients with polyvascular disease, compared to those without. Polyvascular disease is defined as having an acute coronary syndrome (ACS), plus either concurrent peripheral artery disease or cerebrovascular disease, or both.
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Society for Science & the Public announced that Ana Humphrey, 18, of Alexandria, Virginia, won the top award in the Regeneron Science Talent Search, the nation's oldest and most prestigious science and math competition for high school seniors. Forty finalists were honored tonight at the annual Regeneron Science Talent Search awards gala.
The FDA approves a label expansion of Regeneron's (REGN) asthma drug, Dupixent for moderate-to-severe atopic dermatitis in adolescents.
TARRYTOWN, N.Y. and CAMBRIDGE, Mass., March 12, 2019 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today announced that the U.S. Food and Drug Administration (FDA) has approved Dupixent® (dupilumab) for adolescent patients 12 to 17 years of age with moderate-to-severe atopic dermatitis whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable. Dupixent can be used with or without topical corticosteroids. "For the first time, adolescents with uncontrolled moderate-to-severe atopic dermatitis have an approved biologic treatment option to help control persistent, often debilitating symptoms such as chronic itch and widespread rash.
The U.S. Food and Drug Administration said it approved expanded use of Regeneron Pharmaceuticals Inc and Sanofi SA's eczema drug Dupixent to include patients aged between 12 and 17, a boost for both the companies in the world's largest market for drugs. Shares of Regeneron closed up 2.3 percent at $412.05 on Monday. The FDA first approved the drug in 2017 and it has since been launched as a treatment for adults with moderate-to-severe atopic dermatitis, or eczema, as well as a drug for some asthma patients.
CAMBRIDGE, Mass. and TARRYTOWN, N.Y., March 11, 2019 /PRNewswire/ -- The U.S. Food and Drug Administration (FDA) has approved Dupixent® (dupilumab) for adolescent patients 12 to 17 years of age with moderate-to-severe atopic dermatitis whose disease is not adequately controlled with topical prescription therapies, or when those therapies are not advisable. Dupixent can be used with or without topical corticosteroids. "For the first time, adolescents with uncontrolled moderate-to-severe atopic dermatitis have an approved biologic treatment option to help control persistent, often debilitating symptoms such as chronic itch and widespread rash.
The U.S. Food & Drug Administration on Monday approved use of Regeneron Pharmaceuticals Inc and Sanofi SA's eczema drug Dupixent for adolescents aged 12 and older, helping expand the use of an important revenue driver for both the companies in the world's largest market for drugs. The drug was initially approved in 2017 and has since been launched in the United States as a treatment for adults with moderate-to-severe atopic dermatitis, as well as a drug for some asthma patients.
Sanofi (SNY) and partner Regeneron's (REGN) Dupixent gets FDA's priority review status for inadequately controlled severe chronic rhinosinusitis with nasal polyps.
Regeneron (NASDAQ: REGN) and UK Biobank announced today that a vast tranche of new human sequencing data is now available to health researchers, offering an unprecedented 'Big Data' resource to enhance understanding of human biology and aid in therapeutic discovery. The exome sequence data of 50,000 UK Biobank participants were generated at the Regeneron Genetics Center (RGC) through a collaboration between UK Biobank, Regeneron and GlaxoSmithKline (GSK) and are linked to detailed de-identified health records, imaging and other health-related data. Regeneron is also leading a consortium of biopharma companies (including Abbvie, Alnylam, AstraZeneca, Bristol-Myers Squibb, Biogen, Pfizer and Takeda) to complete exome sequencing of the remaining 450,000 UK Biobank participants by 2020.
On Friday an analyst questioned the longevity of a collaboration between Regeneron Pharmaceuticals and Sanofi for a medicine to lower cholesterol that rivals an Amgen drug.
TARRYTOWN, N.Y. , March 8, 2019 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) will webcast management participation as follows: J.P. Morgan 2019 Spring Biotech Conference Call Series at ...
Regeneron (REGN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.